Status:
UNKNOWN
The Effect of MedicijnWijs on Adherence to Azathioprine Therapy in Adolescents With IBD
Lead Sponsor:
Maxima Medical Center
Conditions:
Inflammatory Bowel Diseases
Crohn Disease
Eligibility:
All Genders
12-17 years
Phase:
NA
Brief Summary
Medication non-adherence is an existing problem in patients with inflammatory bowel diseases (IBD). Adherence rates are especially low in children and adolescents. Good medication adherence is key in ...
Detailed Description
Rationale: medication non-adherence is an existing problem in patients with inflammatory bowel diseases (IBD). Adherence rates are especially low in children and adolescents. Good medication adherence...
Eligibility Criteria
Inclusion
- Age: 12 up to and including 17 years old
- Condition: IBD (Crohn's Disease and Ulcerative Colitis)
- Treatment: azathioprine
Exclusion
- \- Inability to use MedicijnWijs due to either low cognitive skills or the unavailability of a phone or other technical device to use the app on
Key Trial Info
Start Date :
March 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 16 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05321485
Start Date
March 16 2022
End Date
September 16 2022
Last Update
April 11 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Catharina Hospital
Eindhoven, North Brabant, Netherlands, 5623EJ
2
Zuyderland Medisch Centrum
Heerlen, North Brabant, Netherlands, 6419PC
3
Maxima Medical Center
Veldhoven, North Brabant, Netherlands, 5500VB